Abstract
Multiple myeloma is the second most common hematologic malignancy. In Multiple myeloma a serum or urine monoclonal component is produced by bone marrow plasma cells. Great progresses have been made in the latest 10 years and survivals are nearly doubled. This improvement has been reached with novel efficacious drugs and with implemented diagnostic tools. The diagnosis is made by serum and urine biochemicals exams, by radiological examination and by marrow analysis. Novel diagnostic parameters have been introduced and novel prognosticators are present. Cytogenetics , flow cytometry, PET-CT are only few of them. Laboratory tools are present that can diagnose, detect and monitor disease during follow up. In this presentation an overview of multiple myeloma diagnostic and therapeutic tools will be given according to recent IMWG recommendations and with practical clinical cases discussed.
Speakers
CAPILLARYS 3 OCTA
Evolution makes the difference.
CAPILLARYS 3 TERA MC
The power of up to 36 capillaries in one automated high volume workcell.
HYDRASHIFT
Avoid interferences due to therapeutic Monoclonal Antibody with HYDRASHIFT Portfolio.
Free Light Chains* (FLC)
The next generation Free Light Chain Assay.
* Under Product Registration approval
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.
Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.